secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0000950170-24-095537
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Q2 net loss $65.1M, cash $778.8M; ACHIEVE/DELIVER data positive
--------------------------------------------------------------------

- Q2 2024 net loss $65.1M ($0.70/sh) vs $64.9M ($1.08/sh) in Q2 2023.
- Cash, cash equivalents and marketable securities $778.8M, funded at least into H2 2026.
- Completed $374.3M public offering (12.075M shares at $31.00) in May 2024.
- DYNE-101 in DM1 showed splicing correction and functional improvement; DYNE-251 in DMD showed dystrophin expression exceeding eteplirsen at 6 months.
- Company plans to provide registration path update for both programs by year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017024095537/0000950170-24-095537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017024095537/dyn-20240812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer